NCT02756728View on ClinicalTrials.gov

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BI-505

Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months

OTHER

High dose melphalan

High dose melphalan (HDM)

OTHER

Autologous stem cell transplantation

Autologous stem cell transplantation (ASCT)

Trial Locations (1)

19104

Perelman School of Medicine/Hospital of the Univ. of Pennsylvania/Abramson Cancer Center, Philadelphia

Sponsors
All Listed Sponsors
lead

BioInvent International AB

INDUSTRY